Search

Regeneron Pharmaceuticals Inc

Avatud

SektorTervishoid

967.03 1.55

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

952.26

Max

971.45

Põhinäitajad

By Trading Economics

Sissetulek

652M

1.9B

Müük

825M

5.1B

P/E

Sektori keskmine

20.335

68.089

Aktsiakasum

18.43

Dividenditootlus

0.41

Kasumimarginaal

38.092

Töötajad

15,410

EBITDA

753M

2.4B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+0.28% upside

Dividendid

By Acuity

Dividenditootlus

Sektori keskmine

0.41%

1.98%

Järgmine tulemuste avaldamine

29. jaan 2027

Järgmine dividendimakse kuupäev

3. dets 2026

Järgmine aktsia dividendi kuupäev (ex-date)

20. nov 2026

Turustatistika

By TradingEconomics

Turukapital

12B

95B

Eelmine avamishind

965.48

Eelmine sulgemishind

967.03

Regeneron Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. nov 2026, 01:02 UTC

Regeneron Pharmaceuticals, Inc. is trading modestly higher in after-hours following a recovery from an earlier session dip, near the upper end of its one-month range.

13. nov 2026, 23:02 UTC

Regeneron Pharmaceuticals, Inc. shares are modestly higher in after-market trading following Friday's close, maintaining strong performance above its 20-day moving average.

12. nov 2026, 21:07 UTC

Regeneron Pharmaceuticals, Inc. shares fell sharply after reaching an early peak, stabilizing near the upper end of its one-month range.

11. nov 2026, 22:51 UTC

Regeneron Pharmaceuticals, Inc. shares are trading higher in after-market hours, currently positioned 11.58% above its 20-day moving average.

10. nov 2026, 23:11 UTC

Regeneron Pharmaceuticals, Inc. shares advanced modestly in after-hours trading, reversing earlier losses and reaching the upper end of their one-month range.

9. nov 2026, 21:07 UTC

News

Regeneron Pharmaceuticals reports positive results from its first-in-human trial of CIDEBsiRNA, with 93% of participants achieving significant liver fat reductions.

6. nov 2026, 23:06 UTC

Regeneron Pharmaceuticals, Inc. shares are trading modestly lower in after-market hours, following a brief rise earlier in the session.

5. nov 2026, 23:03 UTC

Correlated Moves

iShares Biotechnology ETF (IBB) is trading lower in after-market hours, with Regeneron Pharmaceuticals moving in sympathy with IBB amid mixed sector earnings results.

4. nov 2026, 23:02 UTC

Regeneron Pharmaceuticals, Inc. shares are advancing in after-market hours, following a strong performance and remaining significantly above their 20-day moving average.

3. nov 2026, 23:02 UTC

Social Media

Regeneron Pharmaceuticals, Inc. shares declined in after-market trading, pulling back from a brief high to a notable low point following strong performance in prior sessions.

2. nov 2026, 23:02 UTC

News

Regeneron Pharmaceuticals plans to webcast management participation at upcoming investor conferences, including Jefferies on November 17 and Evercore on December 1, 2026.

30. okt 2026, 23:06 UTC

Regeneron Pharmaceuticals, Inc. is trading modestly lower in after-market hours, reversing a trend of three consecutive higher daily finishes.

29. okt 2026, 23:03 UTC

Regeneron Pharmaceuticals, Inc. is trading higher in after-market hours, reflecting strong performance since Thursday's close and reaching a notable peak during the session.

28. okt 2026, 23:02 UTC

News

Canaccord Genuity maintains its Buy rating on Regeneron Pharmaceuticals and raises the price target to $922, contributing to after-market gains.

26. okt 2026, 20:07 UTC

Event
News

Regeneron Pharmaceuticals extends its agreement with BARDA to supply $270 million in additional doses of Inmazeb, ensuring delivery through 2031.

23. okt 2026, 20:51 UTC

Regeneron Pharmaceuticals Inc shares rose during after-market hours, moving higher alongside the broader market amid mixed economic indicators and falling U.S. Treasury yields.

22. okt 2026, 23:51 UTC

Regeneron Pharmaceuticals Inc is trading higher in after-market hours, maintaining a strong position above its 20-day moving average and near the upper end of its one-month range.

21. okt 2026, 19:46 UTC

Regeneron Pharmaceuticals Inc shares fell.

20. okt 2026, 23:02 UTC

Regeneron Pharmaceuticals Inc shares are declining in after-market trading, retracing earlier gains and positioned near the lower end of its recent trading range.

19. okt 2026, 22:56 UTC

Regeneron Pharmaceuticals Inc. is trading modestly higher in after-market hours, maintaining gains above its 20-day moving average and near the upper end of its one-month range.

16. okt 2026, 23:01 UTC

Event

Regeneron receives positive opinion from the European Medicines Agency for an alternative dosing schedule for Libtayo® across all approved indications.

15. okt 2026, 20:07 UTC

News

Regeneron Pharmaceuticals receives a UBS upgrade to Buy with a price target raised to $978, and partners with Sanofi to enhance Dupixent access in Canada.

14. okt 2026, 20:02 UTC

Regeneron Pharmaceuticals Inc shares have risen sharply, supported by strong performance in the Biotechnology sector, remaining well above the previous close.

13. okt 2026, 20:08 UTC

Event

Regeneron Pharmaceuticals announces positive Phase 3 OPTIMA trial results for Pasatru™ in FOP patients, despite shares trading lower during Tuesday's session.

12. okt 2026, 23:11 UTC

Regeneron Pharmaceuticals Inc is trading modestly higher in after-market hours, continuing a positive trend after three consecutive sessions of gains.

9. okt 2026, 20:01 UTC

Regeneron Pharmaceuticals Inc is trading higher, having reached a peak earlier today while remaining below its 20-day moving average.

8. okt 2026, 23:01 UTC

Regeneron Pharmaceuticals Inc is declining in after-market trading, moving lower since Thursday's close and approaching the lower end of its one-month range.

7. okt 2026, 23:45 UTC

Regeneron Pharmaceuticals Inc traded roughly flat in after-market hours, retracing from a post-close peak and remaining below its 20-day moving average.

6. okt 2026, 23:30 UTC

News

Regeneron Pharmaceuticals Inc. is trading modestly lower in after-market hours, continuing a downward trend and positioned near the lower end of its one-month range.

5. okt 2026, 23:05 UTC

Regeneron Pharmaceuticals Inc saw a slight gain in after-market trading, following a flat regular session, but remains below its 20-day moving average.

Võrdlus sarnastega

Hinnamuutus

Regeneron Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

0.28% tõus

12 kuu keskmine prognoos

Keskmine 958.167 USD  0.28%

Kõrge 1,175 USD

Madal 770 USD

Põhineb 24 Wall Streeti analüütiku instrumendi Regeneron Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

24 ratings

16

Osta

8

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
help-icon Live chat